September 18, 2017 | Published Case Study: “Lab Of The Future”
HALIFAX, Sept. 18, 2017 /CNW/ – kneat.com, inc. (TSXV: KSI) (“Kneat” or the “Company”), announces that it has partnered with a key customer to publish a case study entitled “Newly optimized Laboratory Asset Lifecycle Management System supports QC Laboratory of the Future” which is published in The Parental Drug Association (“PDA”) Letter.
“Kneat is delighted to play such a key role in our customer’s innovative lab of the future project”, stated Eddie Ryan, Chief Executive Officer of Kneat. “This is a testament to Kneat’s next generation, innovative software platform which continues to demonstrate its ability to drive productivity, reduce cycle times and increase visibility and compliance”.
The case study outlines the key features of the Kneat Gx platform that enabled the conversion of a manual, paper-based process to a globally centralized electronic system for all QC laboratory asset lifecycle management. The customer re-engineered and streamlined their analytical instrument qualification process and then configured this new process on the Kneat platform. The key features cited were flexibility to configure the newly optimized process to be fully paperless end-to-end, including all testing activities, ability to template protocols and reports, and instant visibility and control of all information across all sites.
- The project resulted in the following benefits:
- global standardization of the laboratory asset lifecycle management process;
- simplified protocol generation, review and pre-approval;
- simplified and paperless protocol execution and discrepancy management;
- simplified protocol post execution review and approval;
- leveraging and reuse of previous lab asset validation information;
- eliminated paper and document manual handling, management, storage and many other manual steps;
- improved audit preparedness;
- improved metrics visibility on all aspects of the process;
- improved information access; and
- enabled faster new asset onboarding cycle time.
Kneat, headquartered in Limerick, Ireland, develops and markets the next generation Kneat Gx software platform. Kneat Gx, enables an end-to-end paperless process for all validations, commissioning and qualification, production execution and quality document management. Kneat Gx allows users to electronically create, approve and execute all deliverables, manage any exceptions and post approve final deliverables in a controlled FDA Part 11/ Eudralex Annex 11 compliant platform. Users with correct permissions can see everything in real time. Customer case studies are reporting productivity improvements in excess of 100% and a higher compliance standard. www.kneat.com.
Cautionary and Forward-Looking Statements
Except for the statements of historical fact contained herein, certain information presented constitutes “forward-looking information” within the meaning of applicable Canadian securities laws. Such forward-looking information, includes, but is not limited to, the ability to generate sales of the Kneat Gx platform, the ability to build relationships with current and prospective customers, the market potential for the Kneat Gx platform, the ability to develop new features for the Kneat Gx platform, and the compliance of the Kneat Gx platform under regulatory audit and inspection. While such forward-looking statements are expressed by the Company, as stated in this release, in good faith and believed by the Company to have a reasonable basis, they are subject to important risks and uncertainties. As a result of these risks and uncertainties, the events predicted in these forward-looking statements may differ materially from actual results or events. These forward-looking statements are not guarantees of future performance, given that they involve risks and uncertainties. The Company does not undertake any obligation to release publicly revisions to any forward-looking statement, except as may be required under applicable securities laws. Investors should not assume that any lack of update to a previously issued forward-looking statement constitutes a reaffirmation of that statement. Continued reliance on forward-looking statements is at an investor’s own risk.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) acceptsresponsibility for the adequacy or accuracy of this release.
For further information: Sarah Oliver, CFO, kneat.com, inc., 2001-1969 Upper Water Street, Halifax, NS, B3J 3R7, T: +353 61 203826, E: email@example.com
Talk to us
Find out how Kneat can make your validation easier, faster, and smarter.
Start your validation revolution by speaking to our experts.